Literature DB >> 33603102

Sophisticated viral quasispecies with a genotype-related pattern of mutations in the hepatitis B X gene of HBeAg-ve chronically infected patients.

Maria Francesca Cortese1,2, Carolina González3, Josep Gregori4,5, Rosario Casillas4,3, Luca Carioti6, Mercedes Guerrero-Murillo7, Mar Riveiro-Barciela8,9, Cristina Godoy3,8, Sara Sopena4,3, Marçal Yll4,3, Josep Quer4,8, Ariadna Rando3, Rosa Lopez-Martinez3, Beatriz Pacín Ruiz4, Selene García-García4, Rafael Esteban-Mur8,9, David Tabernero3,8, Maria Buti8,9, Francisco Rodríguez-Frías3,8.   

Abstract

Patients with HBeAg-negative chronic infection (CI) have not been extensively studied because of low viremia. The HBx protein, encoded by HBX, has a key role in viral replication. Here, we analyzed the viral quasispecies at the 5' end of HBX in CI patients and compared it with that of patients in other clinical stages. Fifty-eight HBeAg-negative patients were included: 16 CI, 19 chronic hepatitis B, 16 hepatocellular carcinoma and 6 liver cirrhosis. Quasispecies complexity and conservation were determined in the region between nucleotides 1255 and 1611. Amino acid changes detected were tested in vitro. CI patients showed higher complexity in terms of mutation frequency and nucleotide diversity and higher quasispecies conservation (p < 0.05). A genotype D-specific pattern of mutations (A12S/P33S/P46S/T36D-G) was identified in CI (median frequency, 81.7%), which determined a reduction in HBV DNA release of up to 1.5 log in vitro. CI patients showed a more complex and conserved viral quasispecies than the other groups. The genotype-specific pattern of mutations could partially explain the low viremia observed in these patients.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33603102      PMCID: PMC7892877          DOI: 10.1038/s41598-021-83762-4

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  44 in total

1.  New insights into the evolutionary rate of hepatitis B virus at different biological scales.

Authors:  You-Yu Lin; Chieh Liu; Wei-Hung Chien; Li-Ling Wu; Yong Tao; Dafei Wu; Xuemei Lu; Chia-Hung Hsieh; Pei-Jer Chen; Hurng-Yi Wang; Jia-Horng Kao; Ding-Shinn Chen
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

2.  Hepatitis B Virus Infection of HepaRG Cells, HepaRG-hNTCP Cells, and Primary Human Hepatocytes.

Authors:  Yi Ni; Stephan Urban
Journal:  Methods Mol Biol       Date:  2017

3.  STRUM: structure-based prediction of protein stability changes upon single-point mutation.

Authors:  Lijun Quan; Qiang Lv; Yang Zhang
Journal:  Bioinformatics       Date:  2016-06-17       Impact factor: 6.937

4.  Characterization of increased drug metabolism activity in dimethyl sulfoxide (DMSO)-treated Huh7 hepatoma cells.

Authors:  S Choi; B Sainz; P Corcoran; S Uprichard; H Jeong
Journal:  Xenobiotica       Date:  2009-03       Impact factor: 1.908

5.  A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients.

Authors:  S Günther; B C Li; S Miska; D H Krüger; H Meisel; H Will
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

6.  Ultra-deep pyrosequencing (UDPS) data treatment to study amplicon HCV minor variants.

Authors:  Josep Gregori; Juan I Esteban; María Cubero; Damir Garcia-Cehic; Celia Perales; Rosario Casillas; Miguel Alvarez-Tejado; Francisco Rodríguez-Frías; Jaume Guardia; Esteban Domingo; Josep Quer
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

7.  Optimizing human hepatocyte models for metabolic phenotype and function: effects of treatment with dimethyl sulfoxide (DMSO).

Authors:  Nikolaos Nikolaou; Charlotte J Green; Pippa J Gunn; Leanne Hodson; Jeremy W Tomlinson
Journal:  Physiol Rep       Date:  2016-11

8.  Pipeline for specific subtype amplification and drug resistance detection in hepatitis C virus.

Authors:  María Eugenia Soria; Josep Gregori; Qian Chen; Damir García-Cehic; Meritxell Llorens; Ana I de Ávila; Nathan M Beach; Esteban Domingo; Francisco Rodríguez-Frías; María Buti; Rafael Esteban; Juan Ignacio Esteban; Josep Quer; Celia Perales
Journal:  BMC Infect Dis       Date:  2018-09-03       Impact factor: 3.090

9.  The viral transactivator HBx protein exhibits a high potential for regulation via phosphorylation through an evolutionarily conserved mechanism.

Authors:  Sergio Hernández; Mauricio Venegas; Javier Brahm; Rodrigo A Villanueva
Journal:  Infect Agent Cancer       Date:  2012-10-18       Impact factor: 2.965

10.  Analysis of hepatitis B virus preS1 variability and prevalence of the rs2296651 polymorphism in a Spanish population.

Authors:  Rosario Casillas; David Tabernero; Josep Gregori; Irene Belmonte; Maria Francesca Cortese; Carolina González; Mar Riveiro-Barciela; Rosa Maria López; Josep Quer; Rafael Esteban; Maria Buti; Francisco Rodríguez-Frías
Journal:  World J Gastroenterol       Date:  2018-02-14       Impact factor: 5.742

View more
  2 in total

1.  Cross-sectional evaluation of circulating hepatitis B virus RNA and DNA: Different quasispecies?

Authors:  Selene Garcia-Garcia; Maria Francesca Cortese; David Tabernero; Josep Gregori; Marta Vila; Beatriz Pacín; Josep Quer; Rosario Casillas; Laura Castillo-Ribelles; Roser Ferrer-Costa; Ariadna Rando-Segura; Jesús Trejo-Zahínos; Tomas Pumarola; Ernesto Casis; Rafael Esteban; Mar Riveiro-Barciela; Maria Buti; Francisco Rodríguez-Frías
Journal:  World J Gastroenterol       Date:  2021-11-07       Impact factor: 5.742

2.  Inspecting the Ribozyme Region of Hepatitis Delta Virus Genotype 1: Conservation and Variability.

Authors:  Beatriz Pacin-Ruiz; María Francesca Cortese; David Tabernero; Sara Sopena; Josep Gregori; Selene García-García; Rosario Casillas; Adrián Najarro; Unai Aldama; Adriana Palom; Ariadna Rando-Segura; Anna Galán; Marta Vila; Mar Riveiro-Barciela; Josep Quer; Gloria González-Aseguinolaza; María Buti; Francisco Rodríguez-Frías
Journal:  Viruses       Date:  2022-01-22       Impact factor: 5.048

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.